Krka d. d (KRK)
Warsaw Stock Exchange · Poland · prices in PLN · close of 22 Oct 2026
Key indicators
| Last close | PLN 1,120.00 |
|---|---|
| 52-week range | 810.00 – 1,200.00 |
| Return, 1 month / 3 months | −1.4% / −0.9% |
| Return, 1 year / 3 years | +29.0% / +164.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 47 |
| Volatility (1 year) | 23.1% |
| Worst drawdown (1 year) | -10.4% |
| Average daily value traded | 0.08M PLN |
| Dividend yield | 15.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Krka is a pharmaceutical company based in Novo Mesto, Slovenia. It develops and makes prescription medicines, over-the-counter products and animal health products, with a focus on generic drugs sold in tablet, capsule and solution forms. Its customers are patients, doctors, pharmacies and wholesalers, and it sells across Central and Eastern Europe and other international markets. The company also produces vitamin and mineral supplements and products for the treatment of cardiovascular, central nervous system and respiratory conditions.
Krka d. d trades under the code KRK on the Warsaw Stock Exchange in Poland, with its price quoted in Polish zloty (PLN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Krka d. d (KRK) trades on the Warsaw Stock Exchange in Poland. It last closed at PLN 1,120.00 on 22 October 2026.
Its price-based Market X-Ray is 79 out of 100 (a strong price profile), ranking 36 of 580 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 29.0% and over the last three months it fell 0.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Warsaw Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.9% | ||
| From 52-week high | -6.5% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.9% | ||
| 6-month return | 12.4% | ||
| 12-month return, skipping the last month | 30.8% | ||
| Stability (higher is calmer) | 96 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -10.4% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.08M PLN | ||
| Zero-volume days | 0.0% | ||
| Income | 83 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 15.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.7% |
|---|---|
| 1 month | −1.4% |
| 3 months | −0.9% |
| 6 months | +12.4% |
| 1 year | +29.0% |
| 3 years | +164.2% |
| 5 years | +177.3% |
Signals
| 50-day / 200-day average | 1,130.12 / 1,047.29 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 18.07 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Jul 2026 | EUR 39.3847 |
| 22 Jul 2025 | EUR 35.0708 |
| 23 Jul 2024 | EUR 32.1017 |
| 18 Jul 2023 | EUR 29.3355 |
| 19 Jul 2022 | EUR 26.8185 |
| 20 Jul 2021 | EUR 22.9772 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Warsaw Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.